Equities analysts expect Uniqure NV (NASDAQ:QURE) to report ($0.73) earnings per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Uniqure’s earnings, with the highest EPS estimate coming in at ($0.61) and the lowest estimate coming in at ($0.88). Uniqure posted earnings per share of ($0.58) during the same quarter last year, which would indicate a negative year-over-year growth rate of 25.9%. The business is expected to announce its next earnings results on Wednesday, March 21st.
According to Zacks, analysts expect that Uniqure will report full year earnings of ($2.97) per share for the current fiscal year, with EPS estimates ranging from ($3.34) to ($2.62). For the next financial year, analysts forecast that the business will post earnings of ($3.29) per share, with EPS estimates ranging from ($5.12) to ($2.13). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover Uniqure.
Uniqure (NASDAQ:QURE) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.40) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.25. Uniqure had a negative return on equity of 170.28% and a negative net margin of 338.39%.
QURE has been the subject of a number of recent analyst reports. Zacks Investment Research lowered Uniqure from a “hold” rating to a “sell” rating in a research report on Wednesday, October 18th. HC Wainwright set a $28.00 target price on Uniqure and gave the stock a “buy” rating in a research report on Thursday, December 7th. Leerink Swann boosted their target price on Uniqure from $19.00 to $26.00 in a research report on Tuesday, November 7th. Oppenheimer reissued a “hold” rating on shares of Uniqure in a research report on Friday, November 24th. Finally, ValuEngine raised Uniqure from a “sell” rating to a “hold” rating in a research report on Tuesday, December 26th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $20.00.
Shares of Uniqure (NASDAQ QURE) traded down $0.49 during trading hours on Tuesday, reaching $17.10. The company’s stock had a trading volume of 562,883 shares, compared to its average volume of 453,150. Uniqure has a fifty-two week low of $4.72 and a fifty-two week high of $21.35. The company has a current ratio of 3.64, a quick ratio of 3.64 and a debt-to-equity ratio of 0.73. The stock has a market cap of $524.53, a price-to-earnings ratio of -6.55 and a beta of 0.72.
In other Uniqure news, SVP Maria E. Cantor sold 5,864 shares of the business’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $20.13, for a total transaction of $118,042.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Matthew C. Kapusta sold 21,690 shares of the business’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $19.87, for a total value of $430,980.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,647 shares of company stock valued at $651,545. Corporate insiders own 0.73% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Mangrove Partners bought a new stake in shares of Uniqure during the 2nd quarter valued at about $247,000. OxFORD Asset Management LLP bought a new stake in shares of Uniqure during the 3rd quarter valued at about $399,000. JPMorgan Chase & Co. grew its stake in shares of Uniqure by 33.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock valued at $362,000 after purchasing an additional 14,659 shares during the period. Finally, FMR LLC grew its stake in shares of Uniqure by 4.1% during the 2nd quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock valued at $9,656,000 after purchasing an additional 61,650 shares during the period. Institutional investors and hedge funds own 24.87% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “-$0.73 Earnings Per Share Expected for Uniqure NV (QURE) This Quarter” was posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://transcriptdaily.com/2018/01/17/0-73-earnings-per-share-expected-for-uniqure-nv-qure-this-quarter.html.
Uniqure Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.